Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. It has a partnership agreement with Gannet BioChem to support development activities for SER-252. Serina Therapeutics, Inc. was founded in 2006 and is headquartered in Huntsville, Alabama.
Add an action for SER.US, or sign in to see your action list.
| Name | Title | Year Born |
|---|---|---|
| Dr. Balkrishan Gill Ph.D. | Executive Co-Chairman of the Board | 1965 |
| Mr. Steven A. Ledger | CEO & Director | 1959 |
| Dr. J. Milton Harris Ph.D. | Co-Founder, Director Emeritus & Chair of Scientific Advisory Board | 1941 |
| Dr. Srini Tenjarla Ph.D. | Chief Technical Operations Officer | 1962 |
| Dr. Randall W. Moreadith M.D., Ph.D. | Chief Development Officer | 1955 |
| Mr. Gregory S. Curhan | Chief Financial Officer | 1962 |
| Dr. Joshua Thomas Ph.D. | Head of Chemistry | NA |
Comprehensive raw data returned from the EOD Fundamentals API. Expand sections below to drill down.